EDIT Editas Medicine, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Editas Medicine, Inc. (EDIT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on April 7, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Editas Medicine, Inc. (EDIT) (SEC CIK 1650664), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 9, 2026 — financial details in Exhibit 99.1
- • EDIT is a clinical-stage gene editing biotech; results signal cash runway and pipeline progress critical to investor thesis
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Editas Medicine, Inc. (EDIT) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 7, 2026 | — | — | — |
8-K | Mar 27, 2026 | — | — | — |
10-K | Mar 9, 2026 | Dec 31, 2025 | — | |
8-K | Mar 9, 2026 | — | Analysis | — |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 12, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 5, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 4, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 5, 2023 | Mar 31, 2023 | — | |
10-K | Feb 22, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 2, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 26, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 6, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest EDIT SEC filings in 2026?
Editas Medicine, Inc. (EDIT) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on April 7, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did EDIT file its most recent 10-K annual report?
Editas Medicine, Inc. (EDIT) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view EDIT 10-Q quarterly reports?
Editas Medicine, Inc. (EDIT)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every EDIT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has EDIT filed recently?
Editas Medicine, Inc. (EDIT)'s most recent 8-K was filed on April 7, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find EDIT insider trading activity (Form 4)?
SignalX aggregates every EDIT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does EDIT file with the SEC?
Editas Medicine, Inc. (EDIT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new EDIT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Editas Medicine, Inc. (EDIT).
What is EDIT's SEC CIK number?
Editas Medicine, Inc. (EDIT)'s SEC CIK (Central Index Key) number is 1650664. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1650664 to look up all EDIT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find EDIT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Editas Medicine, Inc. (EDIT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Editas Medicine, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 44+ filings.